• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Med . Determinants of COVID-19 Disease Severity in Patients With Cancer

tetano

Editor, Senior Moderator
Nat Med


. 2020 Jun 24.
doi: 10.1038/s41591-020-0979-0. Online ahead of print.
Determinants of COVID-19 Disease Severity in Patients With Cancer


Elizabeth V Robilotti[SUP] 1 2 3 [/SUP], N Esther Babady[SUP] 1 4 [/SUP], Peter A Mead[SUP] 1 3 [/SUP], Thierry Rolling[SUP] 1 [/SUP], Rocio Perez-Johnston[SUP] 5 [/SUP], Marilia Bernardes[SUP] 1 [/SUP], Yael Bogler[SUP] 1 [/SUP], Mario Caldararo[SUP] 1 [/SUP], Cesar J Figueroa[SUP] 1 3 [/SUP], Michael S Glickman[SUP] 1 3 [/SUP], Alexa Joanow[SUP] 1 [/SUP], Anna Kaltsas[SUP] 1 3 [/SUP], Yeon Joo Lee[SUP] 1 3 [/SUP], Anabella Lucca[SUP] 1 6 [/SUP], Amanda Mariano[SUP] 1 [/SUP], Sejal Morjaria[SUP] 1 3 [/SUP], Tamara Nawar[SUP] 1 [/SUP], Genovefa A Papanicolaou[SUP] 1 3 [/SUP], Jacqueline Predmore[SUP] 1 [/SUP], Gil Redelman-Sidi[SUP] 1 3 [/SUP], Elizabeth Schmidt[SUP] 1 [/SUP], Susan K Seo[SUP] 1 3 [/SUP], Kent Sepkowitz[SUP] 1 3 [/SUP], Monika K Shah[SUP] 1 3 [/SUP], Jedd D Wolchok[SUP] 3 7 [/SUP], Tobias M Hohl[SUP] 1 3 [/SUP], Ying Taur[SUP] 1 3 [/SUP], Mini Kamboj[SUP] 8 9 10 [/SUP]



Affiliations

Abstract

As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer comprised 8.4% of deceased individuals[SUP]1[/SUP]. Population-based studies from China and Italy suggested a higher coronavirus disease 2019 (COVID-19) death rate in patients with cancer[SUP]2,3[/SUP], although there is a knowledge gap as to which aspects of cancer and its treatment confer risk of severe COVID-19[SUP]4[/SUP]. This information is critical to balance the competing safety considerations of reducing SARS-CoV-2 exposure and cancer treatment continuation. From 10 March to 7 April 2020, 423 cases of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cancer tested). Of these, 40% were hospitalized for COVID-19, 20% developed severe respiratory illness (including 9% who required mechanical ventilation) and 12% died within 30 d. Age older than 65 years and treatment with immune checkpoint inhibitors (ICIs) were predictors for hospitalization and severe disease, whereas receipt of chemotherapy and major surgery were not. Overall, COVID-19 in patients with cancer is marked by substantial rates of hospitalization and severe outcomes. The association observed between ICI and COVID-19 outcomes in our study will need further interrogation in tumor-specific cohorts.
 
Back
Top Bottom